Research Insights

Home » Research & Resources » Research Insights

See what the experts say about the latest published research

Poster Presentations

Concensus Conference Reports

Clinical Management of Drug-Induced Dyskinesia in Parkinson’s Disease: Why Current Approaches May Need to Be Changed to Optimize Quality of Life


Citation: Daneault, J., Vergara-Diaz, G. & Lee, S. I. (2016). Clinical Management of Drug-Induced Dyskinesia in Parkinson’s Disease: Why Current Approaches May Need to Be Changed to Optimise Quality of Life. European Medical Journal, 1, 62-69.

Introduction:

Parkinson’s Disease is a complex degenerative disorder which includes both motor and non-motor symptoms. Many patients who take dopamine replacement therapies to treat the motor symptoms of Parkinson’s Disease experience drug-induced dyskinesia.

  • Dyskinesia: random, uncontrolled, involuntary muscle movements that are a common side effect of long-term use of dopamine replacement therapies with the most common type occurring when the medication reaches its peak (peak-dose dyskinesia).

Research has shown that 30-50% of patients report experiencing dyskinesia within 5 years of starting treatment for PD and 60-100% of patients report dyskinesia within 10 years.  Click here to read the full article.

Poster Presentations

Our research has been presented in major scientific meetings worldwide

Concensus Conference Reports

See what the experts say about key quality of life issues

Follow Us Follow us on TwitterFollow us on FacebookInstagram

Sign Up for Email Alerts

By providing your email you agree to receive periodic emails from The Parkinson Alliance.

Please tell us more about yourself:

This month is? (Anti-Spam)

Contact UsTerms Of UsePrivacy Policy

The Parkinson Alliance is a nonprofit, tax-exempt charitable organization under section 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law. Copyright © 2018 The Parkinson Alliance. All rights reserved.